NCT00705133 - Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

April 30, 2011

Conditions

Pulmonary Arterial HypertensionInterstitial Lung DiseaseIdiopathic Pulmonary Fibrosis

Interventions

DRUG

Treprostinil

For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated

Trial Locations (1)

David Geffen School of Medicine, UCLA, Los Angeles